Incidence and Duration of Cervical Human Papillomavirus 6, 11, 16, and 18 Infections in Young Women: An Evaluation from Multiple Analytic Perspectives
Open Access
- 1 April 2007
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 16 (4), 709-715
- https://doi.org/10.1158/1055-9965.epi-06-0846
Abstract
Objective: To estimate the incidence and duration of cervical human papillomavirus (HPV)-6, HPV-11, HPV-16, and HPV-18 infections in a population of young American women. Methods: The study population consisted of U.S. women who at baseline were 16 to 23 years of age, reported zero to five lifetime sexual partners, never having been pregnant, and never having had a prior abnormal Papanicolaou test and were enrolled in the placebo arm of a randomized multicenter clinical trial of a HPV-16 L1 virus-like particle vaccine. Women underwent type-specific endocervical/ectocervical swab HPV DNA testing at ∼6-month intervals for up to 48 months of follow-up. To contribute person-time in the analyses of type-specific HPV incidence, a woman must have had at least three satisfactory swab specimens available and been negative for the relevant HPV type (HPV-6, HPV-11, HPV-16, or HPV-18) on her first two trial swabs. The duration of incident HPV infections was estimated using Kaplan-Meier survival analysis methods. Results: Person-years of exposure ranged by type-specific analysis from 2,645 to 3,188, with an incidence rate per 100 person-years of 3.6 for HPV-6, 0.4 for HPV-11, 5.4 for HPV-16, and 2.1 for HPV-18. With censoring at the time of treatment for cervical intraepithelial neoplasia, where done, the mean duration of incident infections was 9.3, 8.4, 18.2, and 16.4 months, respectively, for HPV-6 (n = 103), HPV-11 (n = 13), HPV-16 (n = 142), and HPV-18 (n = 62). When the duration of HPV infections was truncated at the time of cervical intraepithelial neoplasia detection (any grade), where applicable, mean duration figures were 8.4, 8.1, 14.0, and 15.1 months for HPV-6, HPV-11, HPV-16, and HPV-18 infections, respectively. Conclusions: Previous studies of the mean duration of cervical HPV infection have been based on prevalent infections and/or featured relatively short duration of follow-up. This study tested women for HPV infection over a period of up to 48 months and observed a mean duration of incident HPV-16/HPV-18 infections approximately twice that of HPV-6/HPV-11. (Cancer Epidemiol Biomarkers Prev 2007;16(4):709–15)Keywords
This publication has 34 references indexed in Scilit:
- Time to clearance of human papillomavirus infection by type and human immunodeficiency virus serostatusInternational Journal of Cancer, 2006
- The cost-effectiveness of human papillomavirus screening for cervical cancerThe European Journal of Health Economics, 2005
- A Longitudinal Study of Genital Human Papillomavirus Infection in a Cohort of Closely Followed Adolescent WomenThe Journal of Infectious Diseases, 2005
- Psychological impact of human papillomavirus testing in women with borderline or mildly dyskaryotic cervical smear test results: cross sectional questionnaire studyBMJ, 2004
- Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysisBritish Journal of Cancer, 2003
- Biotinyl-Tyramide-Based In Situ Hybridization Signal Patterns Distinguish Human Papillomavirus Type and Grade of Cervical Intraepithelial NeoplasiaLaboratory Investigation, 2002
- Incidence, Prevalence, and Clearance of Type‐Specific Human Papillomavirus Infections: The Young Women’s Health StudyThe Journal of Infectious Diseases, 2002
- Persistent infection with human papillomavirus following the successful treatment of high grade cervical intraepithelial neoplasiaBJOG: An International Journal of Obstetrics and Gynaecology, 2002
- Uterine Cervical Dysplasia and CancerDiagnostic Molecular Pathology, 1998
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958